Curcumin enhances the effectiveness of cisplatin by suppressing CD133+ cancer stem cells in laryngeal carcinoma treatment

Citations Over TimeTop 15% of 2013 papers

Abstract

Chemoresistance is one of the major barriers to chemotherapeutic treatment and it has been established that CD133+ cancer stem cells are responsible for drug resistance in laryngeal carcinoma. In the present study, curcumin and cisplatin were used as a combined treatment to induce the sensitivity of CD133+ cancer stem cells to chemotherapeutic agents and to enhance therapeutic effectiveness. The results revealed that in untreated and cisplatin-treated HEp-2 cell groups, the percentage of CD133+ cells was 4.50 and 6.89%, respectively. However, in the combined treatment group, the percentage of CD133+ cells was markedly reduced to 1.49%, indicating that curcumin may increase the sensitivity of CD133+ cells to cisplatin, leading to the suppression of chemoresistance in HEp-2 cells. Furthermore, the expression of ATP-binding cassette sub-family G member 2 (ABCG2), which is an important gene for chemoresistance, was demonstrated to be reduced in CD133+ cancer stem cells following combined treatment. These results suggest that the combined application of curcumin with chemotherapeutic drugs may be a reliable and effective approach for the treatment of laryngeal carcinoma.

Related Papers

• → ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells(2016)77 cited
• → Serum expression levels of microRNA-382-3p, −598-3p, −1246 and −184 in breast cancer patients(2016)57 cited
• → Detection of activated K-ras in non-small cell lung cancer by membrane array: A comparison with direct sequencing(2007)9 cited
• → Expression of RUNX3 gene and miR-363 in colorectal cancer and the relationship with clinicopathological features(2019)4 cited
• Implication of the Expression of BCRP in Breast Cancer Stem Cells(2007)